Rethinking Lupus Nephritis Treatment: Voclosporin vs. High-Dose Steroids
Échec de l'ajout au panier.
Veuillez réessayer plus tard
Échec de l'ajout à la liste d'envies.
Veuillez réessayer plus tard
Échec de la suppression de la liste d’envies.
Veuillez réessayer plus tard
Échec du suivi du balado
Ne plus suivre le balado a échoué
Rethinking Lupus Nephritis Treatment: Voclosporin vs. High-Dose Steroids
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
Early reduction in proteinuria is a key predictor of improved long-term kidney health in lupus nephritis (LN). In this episode, Dr. Anna Wolska from the Lupus Foundation of America speaks with Drs. Maria Dall'Era and Anca Askanase about a new propensity analysis comparing voclosporin-based triple immunosuppressive therapy to traditional high-dose glucocorticoid regimens. They discuss findings from the AURA-LV and AURORA 1 studies, highlighting the safety benefits and earlier proteinuria reduction seen with voclosporin. Tune in to explore how these insights may shape LN treatment guidelines and improve patient outcomes.
Read the paper published in LSM: https://doi.org/10.1136/lupus-2024-001319
Pas encore de commentaire